Vimarsana
Biggest News Aggregation in the World

Page 2 - Binding Proteins News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Binding Proteins. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Binding Proteins Today - Breaking & Trending Today

Innovent Announces Phase 2 study of Mazdutide（IBI362） in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints | Proteins and Peptides - Vimarsana News

Innovent Announces Phase 2 study of Mazdutide（IBI362） in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints | Proteins and Peptides

Published: June 8, 2022

Innovent Announces Phase 2 study of Mazdutide（IBI362） in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints

Source: pipelinereview.com
Related Topics:
United StatesHong KongInnovent BiologicsAdimab IncyteEli LillyLinong JiClinical Development Of InnoventCompany LillyMd Anderson Cancer CenterUniversity People HospitalI Innovent Biologics IncInnovent Announces PhaseChinese ParticipantsObesity Met PrimaryAll Key Secondary EndpointsChinai JunePeking University PeopleLei QianVice PresidentClinical DevelopmentMain BoardStock ExchangeHong Kong LimitedCancer CenterTherapeutic Protein
Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk) | Proteins and Peptides - Vimarsana News

Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk) | Proteins and Peptides

Published: May 30, 2022

Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)

Source: pipelinereview.com
Related Topics:
United StatesChandramauli RawalChintu PatelKashiv BiosciencesDrug AdministrationI Amneal Pharmaceuticals IncCompany Biologics License ApplicationUnited Statesi MayAmneal PharmaceuticalsBiologics License ApplicationCo Chief ExecutiveChief Operating OfficerAcute Myeloid LeukemiaTherapeutic ProteinBinding Proteins
Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer | Proteins and Peptides - Vimarsana News

Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer | Proteins and Peptides

Published: May 2, 2022

Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer

Source: pipelinereview.com
Related Topics:
David MarekJuan Camilo Arjona FerreiraMyovant Sciences Announces European Commission ApprovalEuropean UnionMyovant Sciences IncEuropean CommissionDrug AdministrationI Myovant SciencesAdvanced Hormone Sensitive Prostate CancerSwitzerlandi AprilMyovant SciencesChief Medical OfficerChief Executive OfficerNew England JournalTherapeutic ProteinBinding Proteins
Molecular Partners to Regain Global Rights for MP0310 from Amgen | Proteins and Peptides - Vimarsana News

Molecular Partners to Regain Global Rights for MP0310 from Amgen | Proteins and Peptides

Published: April 27, 2022

Molecular Partners to Regain Global Rights for MP0310 from Amgen

Source: pipelinereview.com
Related Topics:
Patrick AmstutzMolecular PartnersRegain Global RightsUnited Statesi AprilMolecular PartnerTherapeutic ProteinBinding Proteins
Zhittya Genesis Medicine Starts Parkinson's Disease Clinical Trial | Proteins and Peptides - Vimarsana News

Zhittya Genesis Medicine Starts Parkinson's Disease Clinical Trial | Proteins and Peptides

Published: January 13, 2022

Zhittya Genesis Medicine Starts Parkinson’s Disease Clinical Trial

Source: pipelinereview.com
Related Topics:
Jack JacobsDanielc MontanoI Zhittya Genesis Medicine IncZhittya Genesis Medicine Starts ParkinsonDisease Clinical TrialUnited Statesi JanuaryZhittya Genesis MedicineUse ClinicalCompassionate Use Clinical Trial Chief Science OfficerTherapeutic ProteinBinding Proteins